Oncology

Recent data supported the TCR therapy’s pending BLA submission.

Among patients treated at the higher dose level in the investigator-initiated clinical trial, the objective response rate was 50%.

The course kicks off at 8 AM ET on Friday, April 28, 2023, and will feature talks on acute and chronic graft versus host disease, infection risk, vaccination, thrombotic microangiopathy, and maintenance strategies, among others.

The investigators from Children’s Hospital of Philadelphia discussed the potential implications of their research into human adenoviruses for the development of new gene delivery tools.

Next steps may include assessing AFM13 in combination with natural killer cells.

The assistant member at the Department of Biostatistics and Bioinformatics at Moffitt Cancer Center shared the potential implications of the findings he is presenting at the 2023 AACR annual meeting on proteomics and metabolomics.

Among 11 treated patients, 8 achieved a complete response.

Infection rates in patients receiving omidubicel post-stem cell transplant were about 20% less than those in the control group.

The data warrant further evaluation of ALLO-316 in patients with confirmed CD70+ tumors.

CGTLive takes a look at recent progress in cell therapy development targeting solid tumors, featuring expert commentary on these advances.

Review top news and interview highlights from the week ending April 14, 2023.

Cellectis noted that the allogeneic product was manufactured at its new in-house facility in Paris.

Vigil cell therapy previously showed some efficacy as a monotherapy in patients with ovarian cancer.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The CaMMouflage trial dosed its first participant in March 2023.

The assistant professor of medicine at Vanderbilt University Medical Center discussed the work that has been done in the field in the past 10 years and work that still remains to be done.

Verismo Therapeutics’ SynKIR-110 previously received orphan drug designation from the FDA.

Immatics is prioritizing its TCR-T and TCER cell therapy programs and leaving behind its first-generation programs.

Study authors Matthew Charman, PhD, and Matthew D. Weitzman, PhD, elaborated on the findings and implications of their research.

Although the TCB-202-001 trial ended prematurely due to the COVID-19 pandemic, promising results warrant a phase 2 trial.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

Precigen’s investigational UltraCAR-T therapy is being assessed in a dose-escalation and -expansion study that will include patients with solid tumors, chronic lymphocytic leukemia, mantle cell lymphoma, acute lymphoblastic leukemia, and diffuse large B-cell lymphoma.

Review top news and interview highlights from the week ending March 31, 2023.

CB-011 and CB-010 are being evaluated for the treatment of r/r multiple myeloma and r/r B-cell non-Hodgkin lymphoma, respectively.

The Study Safety Committee has recommended that the trial proceed to enroll patients in the highest-dose cohort.

Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.

The FDA will determine the acceptability of the BLA within the next 60 days.

The patient was treated at the new fifth dose level and had concomitant metapneumovirus infection.

Investigators plan to present full results from the OS analysis of the phase 3 ZUMA-7 trial at an upcoming medical meeting.

The barrier is an essential part of keeping the brain safe, but it also prevents the immune system from eliminating brain cancer tumors.